ClinicalTrials.gov
public full text
Public Domain
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour#853718
- HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors#902510
- Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies#1228488
- A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors#1182936
- Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.#1033641
Record · ID 1228494
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive